Open company graph database — free web & API
Login

Kyorin Pharmaceutical Holdings Co., Ltd.

キョーリン製薬ホールディングス株式会社Kyowa Kirin Holdings Co., Ltd.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
4
§01

Basic information

BASIC
Head office
Tokyo, Japan
Chief executive
Toyo Ogiwara
Capital
100,000,000,000  (1,000 100 million)
Employees (non-consolidated)
Employees (consolidated)
Start date
2008-10-01
End date
§02

Websites

1 DOMAINS
§03

Business

7
Research, development, manufacturing, and sales of pharmaceuticalsResearch, manufacturing, and sales of pharmaceuticalsResearch, manufacturing, and sales of biopharmaceuticalsSupport for clinical development of pharmaceuticalsResearch and development of pharmaceuticalsManufacturing of pharmaceuticalsSales of pharmaceuticals
§04

Related companies

4 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Kyorin Pharmaceutical Co., Ltd.
Group Parent
KYORIN Remedio Co., Ltd.
Group Subsidiary
Kyorin Pharmaceutical Group Factory Co., Ltd.
Group Subsidiary
NIPPON RIKA CO., LTD.
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

76 EVENTS

Founder Ogiwara Hiroshi established Toyo Pharmaceutical Company, the predecessor of Kyorin Pharmaceutical, marking the start of its history. In 1923 (Taisho 12), amid the aftermath of the Great Kanto Earthquake, Ogiwara Hiroshi founded Toyo Pharmaceutical Company in Arai-juku, Omori-ku, Tokyo, beginning the company's founding.Sources

Established the Kyorin Chemical Research Institute.Sources

Renamed the Kyorin Chemical Research Institute to Kyorin Pharmaceutical Co., Ltd., and established Kyorin Pharmaceutical (Stock) as an independent sales division.Sources

Opened the Okaya Factory.Sources

Launched the medical journal "Doctor Salon."Sources

Established the Kyorin Chemical Research Institute (later Development Technology Center).Sources

Establishment of the Kyorin Chemical Research Institute (later Development Technology Center)Sources

Headquarters building completed at Kanda SurugadaiSources

Painkiller 'Kyorin AP2' releasedSources

Oral hypoglycemic agent 'Deamerin S' releasedSources

Nogaki factory openedSources

Central Research Institute establishedSources

Merger of Kyorin Pharmaceutical Co., Ltd. and Kyorin Pharmaceutical Co., Ltd.Sources

Nishio factory openedSources

Capital participation in Nichi-ichi Pharmaceutical Co., Ltd. (company name changed to Nichi-ichi Kyorin Pharmaceutical Co., Ltd.)Sources

Inflammatory bowel disease treatment 'Pentasa' releasedSources

'Gachifloxacin' (GFLX) transferred to Bristol-Myers Squibb Co., USASources

Acquisition of 'Milton' business from P&GSources

Listed on Tokyo Stock Exchange Second SectionSources

Designated for Tokyo Stock Exchange First SectionSources

'Gachifloxacin eye drops' transferred to Alcon Inc., USASources

Established Kyorin USA, Inc. (100% owned) in the United StatesSources

Bronchial asthma treatment 'Kipres tablets' releasedSources

Established Kyorin Europe GmbH (100% owned) in GermanySources

Broad-spectrum oral antibacterial 'Gachifloxacin' (GFLX) releasedSources

Made ActivX Biosciences, Inc. in the United States a 100% subsidiarySources

Acquired shares of Toyo Pharma Co., Ltd. (now Kyorin Remedio Co., Ltd.) and made it a subsidiarySources

Closure of the Nogi factorySources

Transition to a holding company structure through a share exchange with Kyorin Co., Ltd.Sources

Merger of Kyorin Pharmaceutical Co., Ltd. and Nichi-ichi Kyorin Pharmaceutical Co., Ltd.Sources

Change of company name from Kyorin Co., Ltd. to Kyorin Pharmaceutical Holdings Co., Ltd.Sources

Acquisition of MSD Shiga plant and establishment of Kyorin Pharmaceutical Group Factory Co., Ltd.Sources

Launch of environmental disinfectant and cleaner 'Rubista'Sources

Relocation of headquarters to Kanda Surugadai 'Ochanomizu Solacity'Sources

Launch of asthma treatment combination drug 'Fullti Form'Sources

Consolidation of the Drug Discovery Institute (formerly Central Research Institute) and Development Research Institute (formerly Research Center) and establishment of Kyorin Pharmaceutical Co., Ltd. Watarase Drug Discovery CenterSources

Launch of COPD treatment drug 'Eclira Genuea'Sources

Transfer of the 'FPR2 agonist program' to Bristol Myers Squibb Co., USASources

Closure of the Okaya factorySources

Launch of montelukast tablets 10mg/5mg 'KM' for bronchial asthma and allergic rhinitisSources

Launch of desloratadine tablets 5mg for allergic diseasesSources

Establishment of Kyorin Remedio Co., Ltd. Takao Pharmaceutical Research InstituteSources

Kyorin Pharmaceutical Co., Ltd. acquires shares of Jitas Co., Ltd. and absorbs it in a merger (entry into diagnostic business)Sources

Operation of new production subsidiary Kyorin Pharmaceutical Group Factory Co., Ltd. (headquarters: Tokyo)Sources

Launch of overactive bladder treatment drug 'Beoova tablets 50mg'Sources

Merger of Kyorin Pharmaceutical Group Factory Co., Ltd. and Kyorin Medical Supply Co., Ltd.Sources

Launch of quinolone oral antibacterial 'Lasbik tablets 75mg'Sources

Closure of ActivX Biosciences, Inc.Sources

Establishment of the founding anniversary. On June 16, 1931 (Showa 6), Kyorin Chemical Research Institute was established. Since it was the first time the name 'Kyorin' was used, this date was set as the founding (commemorative) day of the company group.Sources

Renamed to Kyorin Pharmaceutical. In 1940 (Showa 15), Kyorin Chemical Research Institute was renamed Kyorin Pharmaceutical. That same year, Kyorin Pharmaceutical Products was established to handle the sales division.Sources

Opening of the Okaya factory. In 1947 (Showa 22), after the war, the Okaya factory was opened in Okaya City, Nagano Prefecture. It operated as a main factory until 2016 (Heisei 28).Sources

Establishment of Kyorin Chemical Research Institute. In 1962 (Showa 37), Kyorin Chemical Research Institute was established in Futam, Kita-ku, Tokyo, to develop new drugs. An organized structure was built.Sources

Completion of the headquarters building. In 1965 (Showa 40), the headquarters was moved to Kanda Surugadai, Chiyoda-ku, Tokyo. The headquarters building was completed.Sources

Opening of the Nogi factory. In 1967 (Showa 42), the Nogi factory was opened, and modernization of production equipment to accommodate production expansion progressed. It operated as a main factory from 1967 (Showa 42) to 2006 (Heisei 18).Sources

Opening of the Central Research Institute. In 1977 (Showa 52), in response to the demands of the era, the Central Research Institute was established in Nogi Town, Shimotsuga District, Tochigi Prefecture, to enhance the development of original new drugs. It later contributed to the development of the much-anticipated new drug Norfloxacin (Baxdarel).Sources

Licensing of Norfloxacin to Merck in the United States. In 1980 (Showa 55), Norfloxacin was licensed to Merck in the United States. Contracts were also made with several European pharmaceutical companies, and the drug was sold in more than 130 countries and regions worldwide, earning the company worldwide recognition for its drug discovery capabilities.Sources

Merger of Kyorin Pharmaceutical and Kyorin Pharmaceutical Products. In 1992 (Heisei 4), to consolidate management resources and strengthen corporate structure, Kyorin Pharmaceutical and Kyorin Pharmaceutical Products merged. The newly formed 'Kyorin Pharmaceutical Co., Ltd.' began operations, encompassing functions from research and development to production and sales.Sources

Opening of the Noshiro factory. In 1995 (Heisei 7), to achieve further stable production, stable supply, and improved productivity, the Noshiro factory was opened in Noshiro City, Akita Prefecture. It began operation as a new production site.Sources

Establishment of Nichi-Show Kyorin Pharmaceutical. In 1996 (Heisei 8), aiming for further growth and development through strengthening the pharmaceutical business, a capital investment was made in Nichi-Show Pharmaceutical Co., Ltd. Business activities began as Nichi-Show Kyorin Pharmaceutical Co., Ltd.Sources

Establishment of a research center. In 1996 (Heisei 8), aiming to improve development research functions (synthetic research, safety technology, synthesis technology, formulation technology), a research center was established in Nogi Town, Shimotsuga District, Tochigi Prefecture. Further efficiency in development research was advanced.Sources

Licensing of Gachifloxacin. In 1996 (Heisei 8), the new quinolone antibacterial agent Gachifloxacin was licensed to the U.S. company BMS. In 2000 (Heisei 12), Gachifloxacin eye drops were licensed to the U.S. company Argon.Sources

Acquisition of the Milton business. In 1998 (Heisei 10), the company inherited the Japanese operations of Milton, a sterilizing disinfectant for baby bottles and nipples, from the P&G group. It expanded its infectious disease-related business scope from "treatment" to "prevention" and aimed to strengthen its over-the-counter drug business.Sources

Listing on the Tokyo Stock Exchange Second Section and designation to the First Section. In April 1999 (Heisei 11), the company was listed on the Second Section of the Tokyo Stock Exchange, and the following year it was designated to the First Section. By elevating its social standing and expanding funding options, it aimed to continue investing in R&D and expanding into new business areas.Sources

Acquisition of ActivX as a subsidiary. In 2004 (Heisei 16), the company acquired the biotech venture ActivX to acquire new drug discovery technology (proteomics). This facilitated the efficiency and speed of exploratory research for candidate drug compounds. The subsidiary was closed in 2023 (Reiwa 5).Sources

Group integration of Toyo Pharma. In 2005 (Heisei 17), the company acquired Toyo Pharma Co., Ltd. (now Kyorin Remedio Co., Ltd.) and entered the generic drug business. It worked on building new businesses.Sources

Transition to a holding company structure. In 2006 (Heisei 18), the company transitioned to a holding company structure to realize a new corporate image of a "global drug discovery business at its core, a distinctive integrated healthcare company built on trust." It changed its name to Kyorin Co., Ltd. In 2010 (Heisei 22), it changed its name to Kyorin Pharmaceutical Holdings Co., Ltd. to enhance recognizability and worked to improve its brand awareness.Sources

Establishment of Kyorin Pharmaceutical Group Factory. In 2012 (Heisei 24), to further improve production technology and capacity, the company acquired the MSD Shiga factory. It was established as the Kyorin Pharmaceutical Group Factory and advanced the construction of a new production system.Sources

Kyorin Pharmaceutical Holdings Co., Ltd. and Angel Pharmaceutical Co., Ltd. merge.Sources

Opening of Takao Factory.Sources

Consolidation of domestic R&D sites that were dispersed across two locations: the Drug Discovery Institute (formerly Central Research Institute) and the Development Research Institute (formerly Research Center). The new development research facility, "Watarase Drug Discovery Center," was established on the former Nogi factory site (Nogi Town, Shimotsuga District, Tochigi Prefecture). The company streamlined people, organization, and systems, strengthened collaboration, and built a structure to further demonstrate its overall strength.Sources

To strengthen the development capability of generic drug formulations and increase the number of attractive in-house developed products, the company established the Takaoka Formulation Research Institute in Takaoka City, Toyama Prefecture. It worked on the development of solid and liquid formulations and aimed to improve the quality and speed of formulation development.Sources

Acquisition of all shares of Jitas Co., Ltd., established to industrialize technology developed by the National Institute of Advanced Industrial Science and Technology (AIST). This led to the launch of the ultra-high-speed gene quantification device "GeneSoC" developed by the company. The device, which improved PCR instruments with proprietary technology, is also used for diagnosing COVID-19.Sources

By absorbing and splitting the production headquarters of the Noshima factory and Kyorin Remedio Co., Ltd., the company inherited a new production subsidiary. It also absorbed and merged the Kyorin Pharmaceutical Group Factory in Koka City, Shiga Prefecture into the new production subsidiary, operating the new subsidiary Kyorin Pharmaceutical Group Factory Co., Ltd. The company built a competitive production system that optimizes overall production within the group and supplies high-quality products at a stable low cost.Sources

The company reorganized from four market segments to three, and the group chose to list on the top-tier Prime market. It met criteria such as performance and stock liquidity, and further advanced its response to corporate governance and sustainability issues.Sources

Celebrated its 100th anniversary.Sources

Merged with its wholly-owned subsidiary, Kyorin Pharmaceutical, and changed its name to Kyorin Pharmaceutical Co., Ltd.Sources

§07

News

1 ARTICLES

Special Report (Change of Major Shareholders)Sources

On October 29, 2026, we released a special report concerning the change of major shareholders. For details, please see the published PDF.

§09

Sources & updates

SOURCES
↑